NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating C

Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's aft

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopha

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformati

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopha

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in

Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-m

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopha

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launche

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therape

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst c

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expe

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on

AAPL: 4% | Apple shares are trading higher after the company reported better-than-expected Q2 financ

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Cue Biopharma, Inc. (NASDAQ:CUE) shares are tumbling on Wednesday after the company announced a reve

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Cue Biopharma (NASDAQ: CUE) held its annual meeting of stockholders virtually, with Interim Presiden

Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL)

The biopharmaceutical company is developing injectable biologics to selectively engage and modulate

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional mi

GAME stock rose 52.3% in pre-market trading after reporting positive EBITDA and financials. Other ga

Preclinical milestone for selection and approval of first compound for lead optimization has been ac

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammato

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel cla

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Virtual Event will feature Key Opinion Leaders (KOLs)  Richard DiPaolo, PhD, and Jonathan Kay, MD, F